Photo: Yuria-Pharm
The Ukrainian pharmaceutical company Yuria-Pharm finished 2024 with a net profit of UAH 750 million, which is UAH 180 million more than in the previous year. This is reported by RBC-Ukraine with reference to Opendatabot data.
In 2024, the company’s total revenue reached UAH 5.7 billion, which is almost a billion more than in 2023 (UAH 4.8 billion). Despite the growth, the company still hasn’t reached its record profit figure, which was recorded in 2021, when it was almost UAH 1 billion.
Yuria-Pharm is owned by entrepreneur Mykola Humeniuk, who is ranked 79th in the Forbes list of the richest Ukrainians.
Amid economic growth, the company also supported the initiative to reduce drug prices. In February 2025, President Volodymyr Zelenskyy announced the launch of a programme to reduce the price of the 100 most popular medicines by 30%. The decision was approved by the National Security and Defence Council and enshrined in Presidential Decree No. 82/2025.
Yuria-Pharm joined the initiative by agreeing to reduce prices for six medicines, including:
– Sodium chloride (100 ml and 200 ml),
– Rheosorbilact,
– Tivortin,
– Glucose,
– Decadence.
These actions demonstrate the company’s commitment not only to maintaining high profitability but also to participating in socially significant initiatives at the national level.
